DFDaniela Fignani

Daniela Fignani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daniela Fignani has a total of 112 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hippo signaling-linked circulating microRNA networks are associated with cardiovascular disease in type 2 diabetes

    by Zein Mersini Besharat, Sofia Trocchianesi, Giuseppina Emanuela Grieco, Tanja Milena Autilio, Caterina Alfano, Angela Dardano, Daniela Fignani, Elena Splendiani, Anna Citarella, Claudia Sabato, et al.

    Context: Type 2 diabetes (T2D) markedly increases the risk of cardiovascular disease (CVD). Circulating microRNAs (miRNAs) are promising biomarkers for patient stratification and may provide mechanistic insight into dysregulated pathways in T2D-associated CVD. Objective: This work aimed to identify circulating miRNA signatures in T2D patients with CVD (T2D-CVD) vs T2D patients without CVD using a novel network-based medicine approach. Methods: Patients (n = 110) were stratified into T2D and T2D-CVD groups based on the absence or presence of macrovascular complications. Circulating miRNAs, proinflammatory cytokines, and growth factors were profiled in a discovery cohort (n = 80) and confirmed in a validation cohort (n = 30). Differential expression, network-based approaches, and pathway enrichment analyses identified miRNA signatures, coexpression communities, hub miRNAs, and associated signaling pathways. Results: T2D-CVD patients showed a set of elevated inflammatory cytokines and circulating miRNAs. Particularly, 19 miRNAs were differentially expressed between T2D-CVD and T2D patients. Pathway enrichment of these miRNAs highlighted Hippo signaling together with transforming growth factor-β, mechanistic target of rapamycin, Wnt, and PI3K-Akt pathways. Network analysis identified a coexpression community of 34 miRNAs, including hub miRNAs let-7a-5p, miR-132-3p, and miR-1306-3p, all linked to Hippo signaling. Key miRNA interactions were validated, and differentially expressed and hub miRNAs both correlated with inflammatory mediators such as PAR-1, CXCL1, and NEMO, which are linked to Hippo pathway regulation. Conclusion: This study identified a network of circulating miRNAs associated with inflammatory cytokines and Hippo signaling pathway in T2D-CVD. These findings reveal novel molecular aspects of the systemic inflammation characterizing T2D-CVD and support the potential of Hippo-related circulating miRNAs as mechanistic biomarkers for cardiovascular risk in T2D.


  • Plasma small RNA profiling reveals a three-miRNA signature associated with early beta cell dysfunction across glucose tolerance stages

    by Elena Aiello, Giuseppina Emanuela Grieco, Michela Brunetti, Giulia Gliozzo, Daniela Fignani, Giuseppe Quero, Sergio Alfieri, Gianfranco Di Giuseppe, Gea Ciccarelli, Angela Dardano, et al.

    Type 2 diabetes mellitus is a multifactorial disease marked by progressive beta cell dysfunction; however, no reliable, easily measurable circulating biomarkers are currently available to track this decline. As microRNAs (miRNAs) tightly regulate beta cell physiology and are secreted and found in blood, we investigated whether specific circulating miRNAs reflect in vivo beta cell function in living donors. We conducted a cross-sectional study on two independent cohorts: a discovery cohort comprising 78 individuals with different levels of glucose tolerance [23 with normal glucose tolerance (NGT), 22 with impaired glucose tolerance (IGT) and 33 with type 2 diabetes] and a validation cohort comprising 158 individuals (71 non-diabetic individuals and 87 with type 2 diabetes) who were administered an oral glucose tolerance test (OGTT) and/or a mixed meal test (MMT) with measurement of glucose, insulin and C-peptide. We profiled plasma RNA by small RNA sequencing, and analysed differences between glucose tolerance groups using DESeq2. We used linear regression analyses to determine the association between miRNA abundance and clinical and metabolic measures. We validated selected miRNAs using droplet digital PCR (ddPCR). Finally, we specified a set of features that were used as an input for a LASSO model to select a biomarker signature that was able to estimate beta cell rate sensitivity (RS) values as a measure of beta cell function. We identified 11 miRNAs that were differentially expressed across the three glucose tolerance groups of the discovery cohort. Integrated analyses pinpointed a three-miRNA signature (miR-34a-5p, miR-1306-5p and miR-335-5p) that correlated with beta cell RS, which is an early indicator of insulin secretory impairment. We incorporated this panel of selected miRNAs with age and 1 h post-load glucose into a LASSO regression model that enabled discrimination of RS values (Spearman's ρ=0.43, p<0.05). We also confirmed model performance in an additional cohort of 71 non-diabetic individuals and 87 individuals with type 2 diabetes (Spearman's ρ=0.23, p<0.05). To provide proof of concept for potential clinical use, we substituted basal glucose for 1 h post-load glucose while retaining miRNA levels and age; this adaptation preserved the significance of the model in the discovery cohort (Spearman's ρ=0.46, p<0.05), and showed an interesting, but not significant, association in the validation cohort (Spearman's ρ=0.15, p=0.061). This three-miRNA signature combined with simple clinical parameters constitutes a promising biomarker for early beta cell dysfunction and type 2 diabetes progression that deserves further validation in additional cohorts.


  • Open Access

    Small non-coding RNA profiling reveals inflammatory and mitochondrial related changes in aging β-cells and islet macrophages

    by Claudiane Guay, Jérôme Perrard, Eleonora Mangano, Véronique Menoud, Elena Aiello, Daniela Fignani, Francesco Dotta, Susan Bonner-Weir, Guido Sebastiani, Cristina Aguayo-Mazzucato, et al.

    Aging is accompanied by functional decline and increased senescence of pancreatic β-cells. These changes may be influenced by islet-resident macrophages (iMACs) that remodel tissue in response to environmental cues. To explore the molecular mechanisms underlying β-cell aging and senescence, we profiled small non-coding RNAs (sncRNAs) in FACS-sorted β-cells and iMACs from 3-, 12-, and 22-month-old mouse islets or from senescence-associated βgal (SA-βgal) positive β-cells of 8-month-old mice. Overall, senescent β-cells displayed distinct sncRNA signatures that only partially overlapped with those of aging. However, several miRNAs previously found to be deregulated in obese or diabetic conditions were modulated in both aging and senescent β-cells, including upregulation of miRNAs linked to inflammation. In vitro exposure to pro-inflammatory cytokines partially reproduced these profiles. Aging also reshaped the β-cell tRNA-derived fragment (tRF) pool, enhancing global mitochondrial tRF levels. Interestingly, some changes in miRNAs and tRFs were β-cell specific, whereas others occurred also in other aged metabolic tissues. iMACs also showed age-related sncRNA remodeling, including upregulation of anti-inflammatory miRNAs and mitochondrial tRFs, suggesting adaptive immune reprogramming. Together, these data reveal a profound, coordinated reshaping of the sncRNA landscape in β-cells and iMACs during aging, offering new insights into molecular mechanisms driving age-related islet dysfunction.

  • Open Access

    Plasma Small RNA profiling reveals a predictive three-miRNAs signature for early beta cell dysfunction across glucose tolerance stages

    by Elena Aiello, Giuseppina Emanuela Grieco, Michela Brunetti, Giulia Gliozzo, Daniela Fignani, Giuseppe Quero, Sergio Alfieri, Gianfranco Di Giuseppe, Gea Ciccarelli, Angela Dardano, et al.

    Aims/hypothesis: Type 2 diabetes mellitus (T2D) is a multifactorial disease marked by progressive beta cell dysfunction; however, no reliable, easily measurable and non-invasive circulating biomarkers are currently available to track this decline. Since microRNAs (miRNAs) tightly regulate beta cell physiology and are secreted and found in blood, we investigated whether specific circulating miRNAs may reflect in vivo beta cell function in living donors. Methods: We conducted a cross-sectional study on two independent cohorts: a discovery cohort composed by 78 individuals with different glucose tolerance [23 with normal glucose tolerance (NGT), 22 with impaired glucose tolerance (IGT), and 33 with T2D] and a validation cohort composed by 158 subjects [71 non-diabetic (ND) and 87 with T2D] who were administered an oral glucose tolerance test (OGTT) and/or a mixed meal test (MMT) with measurement of glucose, insulin and C-peptide. Plasma RNA was profiled by small RNA sequencing and differences between glucose tolerance groups were analysed using DESeq2. Linear regression analyses were used to associate miRNA abundance to clinical and metabolic measures. Droplet Digital PCR (ddPCR) was used to validate selected miRNAs. A LASSO model was used to select a set of features predictive of beta cell function. Results: We identified eleven differentially expressed miRNAs across the three glucose tolerance groups of the discovery cohort. Integrated analyses pinpointed a three-miRNAs signature (miR-34a-5p, miR-1306-5p and miR-335-5p) each significantly correlated with beta cell rate sensitivity (RS), an early indicator of insulin secretory impairment. Incorporating this panel with age and 1-hour post-load glucose into a LASSO regression model enabled accurate prediction of RS (Spearman ρ=0.43, p<0.05). Model performance was confirmed in the validation cohort of 71 ND and 87 T2D subjects (Spearman ρ=0.23, p<0.05). To streamline its clinical use, we substituted fasting glucose for 1-hour post-load glucose while retaining miRNA levels and age; this adaptation preserved predictive power (Spearman ρ=0.46, p<0.05 discovery; ρ=0.15, p=0.06 validation). Conclusion/interpretation: This three-miRNAs signature combined with simple clinical parameters constitutes a promising, non-invasive biomarker for early beta cell dysfunction and T2D progression. Research in context: What is already known about this subject?: Beta cell dysfunction is a key event in Type 2 Diabetes (T2D) pathogenesis Circulating microRNAs (miRNAs) are biomarkers linked to T2D onset and T2D-associated metabolic abnormalities What is the key question?: Can specific circulating miRNAs serve as reliable biomarkers of beta cell dysfunction across different stages of glucose tolerance and Type 2 Diabetes (T2D)? What are the new findings?: Small RNA profiling of plasma samples from deep metabolically characterized NGT, IGT, and T2D subjects revealed circulating miRNAs significantly associated with in-vivo beta cell function, reflecting key mechanisms underlying pancreatic beta cell physiology A specific set of three circulating miRNAs- miR-34a-5p, miR-1306-5p and miR-335-5p - resulted linked to beta cell dysfunction This three-miRNA signature can predict early alterations in insulin secretion, representing a promising non-invasive biomarker for the early identification of individuals at risk of developing T2D How might this impact on clinical practice in the foreseeable future?: Integrating circulating miRNA profiling with routine baseline clinical parameters could provide a simpler, non-invasive, and more accessible method to identify individuals at risk of beta cell dysfunction and T2D. Implementing miRNA-based diagnostics could facilitate personalized monitoring of disease progression. Graphical

  • Open Access

    Functional recovery of islet β cells in human type 2 diabetes: Transcriptome signatures unveil therapeutic approaches

    by Mara Suleiman, Toshiaki Sawatani, Marta Tesi, Xiaoyan Yi, Theodora Papadopoulou, Chantal Rufer, Maria Lytrivi, Emanuele Bosi, Frederic Burdet, Federica Fantuzzi, et al.

    Remission of type 2 diabetes (T2D) can occur after hypocaloric diet, bariatric surgery, or pharmacological treatments and associates with improved β cell function. Here, we studied islets from nondiabetic ( n = 15) and T2D ( n = 21) donors. We examined whether T2D β cell dysfunction can be rescued, charted the underlying molecular mechanisms by RNA sequencing, and mined transcriptomes for drug targets. Glucose responsiveness of T2D β cells improved in 60% of preparations after 3-day culture in euglycemic conditions. This was accompanied by changes in expression of >400 genes involved in functional or inflammatory pathways. Drug repurposing and target identification analyses predicted chemical and genetic hits, including JAK inhibitors, which were validated in a β cell line, human islets, and db/db mice. Therefore, defective β cell glucose responsiveness in T2D can recover, demonstrating β cell functional plasticity. The recovery associates with transcriptomic traits, pointing to targetable defects to induce T2D remission.


  • Open Access

    Comprehensive sequencing profile and functional analysis of IsomiRs in human pancreatic islets and beta cells

    by Stefano Auddino, Elena Aiello, Giuseppina E. Grieco, Daniela Fignani, Giada Licata, Marco Bruttini, Alessia Mori, Andrea F. Berteramo, Erika Pedace, Laura Nigi, et al.

    Aims/hypothesis: MiRNAs regulate gene expression, influencing beta cell function and pathways. Isoforms of miRNA (isomiRs), sequence variants of miRNAs with post-transcriptional modifications, exhibit cell-type-specific expression and functions. Despite their biological significance, a comprehensive isomiR profile in human pancreatic islets and beta cells remains unexplored. This study aims to profile isomiR expression in four beta cell sources: (1) laser capture microdissected human islets (LCM-HI); (2) collagenase-isolated human islets (CI-HI); (3) sorted beta cells; and (4) the EndoC-βH1 beta cell line, and to investigate their potential role in beta cell function. Methods: Small RNA-seq and/or small RNA dataset analysis was conducted on human pancreatic islets and beta cells. Data were processed using the sRNAbench bioinformatics pipeline to classify isomiRs based on sequence variations. A beta cell-specific isomiR signature was identified via cross-validation across datasets. Correlations between LCM-HI isomiR expression and in vivo clinical parameters were analysed using regression models. Functional validation of isomiR-411-5p-Ext5p(+1) was performed via overexpression in EndoC-βH1 cells and CI-HI, followed by glucose-stimulated insulin secretion (GSIS) assays and/or transcriptomic analysis. Results: IsomiRs constituted 59.2 ± 1.9% (LCM-HI), 59.6 ± 2.4% (CI-HI), 42.3 ± 7.2% (sorted beta cells) and 43.8 ± 1.2% (EndoC-βH1) of total miRNA reads (data represented as mean ± SD), with 3′ end trimming (Trim3p) being the predominant modification. A beta cell-specific isomiR signature of 30 sequences was identified, with isomiR-411-5p-Ext5p(+1) showing a significant inverse correlation with basal insulin secretion (p=0.0009, partial R 2=0.68) and total insulin secretion (p=0.005, partial R 2=0.54). Overexpression of isomiR-411-5p-Ext5p(+1), but not of its canonical counterpart, importantly reduced GSIS by 51% ( ± 15.2%; mean ± SD) (p=0.01) in EndoC-βH1 cells. Transcriptomic analysis performed in EndoC-βH1 cells and CI-HI identified 47 genes significantly downregulated by isomiR-411-5p-Ext5p(+1) (false discovery rate [FDR]p=1.1 × 10⁻⁹). Conclusions/interpretation: This study provides the first comprehensive isomiR profiling in human islets and beta cells, revealing their substantial contribution to miRNA regulation. IsomiR-411-5p-Ext5p(+1) emerges as a distinct key modulator of insulin secretion and granule dynamics in beta cells. These findings highlight isomiRs as potential biomarkers and therapeutic targets for diabetes, warranting further exploration of their roles in beta cell biology. Graphical


  • Open Access

    Angiotensin I‐converting enzyme type 2 expression is increased in pancreatic islets of type 2 diabetic donors

    by Daniela Fignani, Erika Pedace, Giada Licata, Giuseppina Emanuela Grieco, Elena Aiello, Carmela de Luca, Lorella Marselli, Piero Marchetti, Guido Sebastiani, Francesco Dotta

    Aims: Angiotensin I‐converting enzyme type 2 (ACE2), a pivotal SARS‐CoV‐2 receptor, has been shown to be expressed in multiple cells, including human pancreatic beta‐cells. A putative bidirectional relationship between SARS‐CoV‐2 infection and diabetes has been suggested, confirming the hypothesis that viral infection in beta‐cells may lead to new‐onset diabetes or worse glycometabolic control in diabetic patients. However, whether ACE2 expression levels are altered in beta‐cells of diabetic patients has not yet been investigated. Here, we aimed to elucidate the in situ expression pattern of ACE2 in Type 2 diabetes (T2D) with respect to non‐diabetic donors which may account for a higher susceptibility to SARS‐CoV‐2 infection in beta‐cells.Material and Methods: Angiotensin I‐converting enzyme type 2 immunofluorescence analysis using two antibodies alongside insulin staining was performed on formalin‐fixed paraffin embedded pancreatic sections obtained from n = 20 T2D and n = 20 non‐diabetic (ND) multiorgan donors. Intensity and colocalisation analyses were performed on a total of 1082 pancreatic islets. Macrophage detection was performed using anti‐CD68 immunohistochemistry on serial sections from the same donors.Results: Using two different antibodies, ACE2 expression was confirmed in beta‐cells and in pancreas microvasculature. Angiotensin I‐converting enzyme type 2 expression was increased in pancreatic islets of T2D donors in comparison to ND controls alongside with a higher colocalisation rate between ACE2 and insulin using both anti‐ACE2 antibodies. CD68+ cells tended to be increased in T2D pancreata, in line with higher ACE2 expression observed in serial sections.Conclusions: Higher ACE2 expression in T2D islets might increase their susceptibility to SARS‐CoV‐2 infection during COVID‐19 in T2D patients, thus worsening glycometabolic outcomes and disease severity.


  • Open Access

    Intra-islet insulin synthesis defects are associated with endoplasmic reticulum stress and loss of beta cell identity in human diabetes

    by Noemi Brusco, Guido Sebastiani, Gianfranco Di Giuseppe, Giada Licata, Giuseppina E. Grieco, Daniela Fignani, Laura Nigi, Caterina Formichi, Elena Aiello, Stefano Auddino, et al.

    Aims/hypothesis: Endoplasmic reticulum (ER) stress and beta cell dedifferentiation both play leading roles in impaired insulin secretion in overt type 2 diabetes. Whether and how these factors are related in the natural history of the disease remains, however, unclear. Methods: In this study, we analysed pancreas biopsies from a cohort of metabolically characterised living donors to identify defects in in situ insulin synthesis and intra-islet expression of ER stress and beta cell phenotype markers. Results: We provide evidence that in situ altered insulin processing is closely connected to in vivo worsening of beta cell function. Further, activation of ER stress genes reflects the alteration of insulin processing in situ. Using a combination of 17 different markers, we characterised individual pancreatic islets from normal glucose tolerant, impaired glucose tolerant and type 2 diabetic participants and reconstructed disease progression. Conclusions/interpretation: Our study suggests that increased beta cell workload is accompanied by a progressive increase in ER stress with defects in insulin synthesis and loss of beta cell identity. Graphical


  • Immunoregulated insulitis and slow-progressing type 1 diabetes after duodenopancreatectomy

    by Pauline Faucher, Frédéric Beuvon, Daniela Fignani, Guido Sebastiani, Georgia Afonso, Zhicheng Zhou, Bertrand Dousset, Christian Boitard, Francesco Dotta, Roberto Mallone, et al.

    Aims/hypothesis We report the case of a woman who underwent a partial pancreatectomy for a serous cystadenoma when aged 56 years. She had been diagnosed with diabetes 6 years before and had Hashimoto’s thyroiditis. Despite positive anti-GAD autoantibodies (GADA) and previous surgery, she was transiently weaned off long-acting insulin. Blood glucose levels remained well controlled with low-dose long-acting insulin. Insulin needs eventually increased 8 years after surgery, in conjunction with anti-zinc transporter 8 (ZnT8) seroconversion and decreasing residual C-peptide. We hypothesised that the surgical pancreas specimens and blood autoimmune T cell responses may provide correlates of this indolent clinical course. Methods Beta and alpha cell area and insulitis were quantified on pancreas head tissue sections obtained at surgery. Blood T cell responses against beta cell antigens were analysed by enzyme-linked immunospot. Results Pancreas sections displayed reduced beta cell and normal alpha cell area (0.27% and 0.85% of section area, respectively). High-grade insulitis was observed, mostly in insulin-containing islets, with a peri-insulitis pattern enriched in T cells positive for regulatory forkhead box protein 3 (FOXP3). In vitro challenge with beta cell antigens of circulating T cells collected 4 and 9 years after surgery revealed dominant and persistent IL-10 responses; IFN-γ responses increasing at 9 years, after anti-ZnT8 seroconversion, was observed. Conclusions/interpretation Despite persistent GADA and the histopathological finding of insulitis and decreased beta cell area 6 years after diabetes diagnosis, glycaemic control was maintained with low-dose insulin up to 8 years after surgery. Regulated T cell responses towards beta cell antigens and FOXP3-positive peri-insulitis suggest spontaneous long-term regulation of islet autoimmunity after substantial beta cell loss, and eventual autoimmune progression upon anti-ZnT8 seroconversion. Graphical abstract


  • Open Access

    Protocol to analyze circulating small non-coding RNAs by high-throughput RNA sequencing from human plasma samples

    by Giuseppina E. Grieco, Guido Sebastiani, Daniela Fignani, Noemi Brusco, Laura Nigi, Caterina Formichi, Giada Licata, Marco Bruttini, Romina D’aUrizio, Chantal Mathieu, et al.